Vasculogenic Cell Generation via SPC and TGFβ Differentiation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for harnessing the differentiation potential of human pluripotent stem cells are limited by an incomplete understanding of the factors governing their differentiation, making it challenging to generate scalable sources of differentiated and precursor cells suitable for therapeutic tissue engineering.
Innovation Solution
A method is developed to generate isolated populations of primate vasculogenic cells by contacting a colony of primate mesenchymal progenitors with a serum-free culture medium containing sphingosylphosphorylcholine (SPC) and Transforming Growth Factor Beta (TGFβ), and culturing them on a coated plate to promote differentiation and isolation of vasculogenic cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional methods for differentiating human pluripotent stem cells are used, then access to differentiated cell types is provided, but the understanding of differentiation factors remains incomplete and scalability is limited
Solution Approach 1:
The patent applies parameter changes by systematically varying growth factor concentrations, culture medium compositions, and differentiation protocols to optimize cell generation. Specific parameter modifications include using defined media with precise growth factor dosing (e.g., FGF2, VEGF, TGFβ) and controlling culture conditions to achieve scalable production of vasculogenic cells while maintaining differentiation reliability.
Solution Approach 2:
The patent implements feedback mechanisms through monitoring cell differentiation markers, proliferation rates, and culture conditions. Quality control parameters are established to verify cell identity and purity at each stage, allowing real-time adjustments to differentiation protocols and ensuring consistent, scalable production of therapeutic cell populations.
2Productivity
If pluripotent stem cells are differentiated into specialized cell types, then therapeutic cell sources are generated, but incomplete understanding of differentiation factors limits the process
Solution Approach 1:
The patent applies preliminary action by pre-establishing differentiation protocols and growth factor regimens before cell production begins. Defined media formulations with predetermined growth factor concentrations are prepared in advance, and differentiation timelines are optimized to ensure efficient cell generation while maintaining control over the differentiation process.
Solution Approach 2:
The patent replaces complex, poorly understood biological differentiation mechanisms with defined chemical and physical culture conditions. Instead of relying on incomplete understanding of natural differentiation factors, the system uses controlled media compositions with specific growth factors (FGF2, VEGF, TGFβ) and defined physical parameters to achieve reliable and scalable cell differentiation.
3Adaptability or versatility
If scalable sources of differentiated cells are developed, then therapeutic tissue engineering is enabled, but current methods lack purity and scalability
Solution Approach 1:
The patent applies segmentation by dividing the differentiation process into distinct temporal and spatial stages. Separate culture conditions are used for different cell types (e.g., endothelial vs. pericyte differentiation), and purification steps are incorporated at specific stages to ensure high cell population purity while maintaining scalability through standardized protocol modules.
Solution Approach 2:
The patent uses parameter changes to achieve both scalability and purity by optimizing culture conditions at each differentiation stage. Specific growth factor concentrations, media compositions, and culture time parameters are precisely controlled to generate pure cell populations that can be scaled up for therapeutic applications without compromising quality.
Data Source
AI summary
The present invention relates generally to methods and compositions useful for therapeutic vascular tissue engineering. In particular, the present invention provides methods for generating substantially pure populations of vasculogenic cells from human mesenchymal progenitor, and methods and compositions for clinical applications in the field of regenerative medicine.